Table 3 Multivariate analysis (Cox regression) for the overall survival and time to leukemia transformation in MDS patients
| Â | Overall survival | Time to leukemia transformation | ||
|---|---|---|---|---|
Variable | HR (95% CI) | P value* | HR (95% CI) | P value* |
FAB-defined MDS patients | ||||
 Age > 65 | 1.512 (1.134–2.016) | 0.005 | 0.656 (0.417–1.031) | 0.067 |
 Male vs female | 1.104 (0.818–1.491) | 0.517 | 0.967 (0.615–1.521) | 0.886 |
 IPSS-R higher risk# | 3.239 (2.199–4.772) | < 0.001 | 5.258 (2.639–10.477) | < 0.001 |
 DNMT3A mutation | 1.733 (1.118–2.688) | 0.014 | 3.088 (1.574–6.056) | 0.001 |
 ASXL1 mutation | 2.010 (1.434–2.818) | < 0.001 | 3.396 (2.075–5.556) | < 0.001 |
 EZH2 mutation | 1.019 (0.597–1.741) | 0.945 | 0.885 (0.416–1.880) | 0.750 |
 TET2 mutation | 1.416 (0.974–2.059) | 0.068 | 1.398 (0.739–2.644) | 0.303 |
 RUNX1 mutation | 1.134 (0.773–1.663) | 0.519 | 1.751 (1.026–2.987) | 0.040 |
 SF3B1 mutation | 1.071 (0.679–1.691) | 0.767 | 1.392 (0.699–2.771) | 0.347 |
 TP53 mutation | 8.254 (5.338–12.762) | < 0.001 | 6.653 (3.183–13.909) | < 0.001 |
2016 WHO-defined MDS patients | ||||
 Age > 65 | 1.649 (1.173–2.319) | 0.004 | 0.731 (0.444–1.203) | 0.217 |
 Male vs female | 1.184 (0.822–1.705) | 0.364 | 0.988 (0.596–1.637) | 0.963 |
 IPSS-R higher risk# | 3.840 (2.432–6.063) | < 0.001 | 5.078 (2.390–10.787) | < 0.001 |
 DNMT3A mutation | 1.800 (1.080–3.000) | 0.024 | 2.360 (1.129–4.933) | 0.022 |
 ASXL1 mutation | 1.830 (1.208–2.774) | 0.004 | 3.596 (2.092–6.182) | < 0.001 |
 EZH2 mutation | 1.196 (0.536–2.668) | 0.662 | 0.927 (0.299–2.875) | 0.896 |
 TET2 mutation | 1.367 (0.841–2.223) | 0.208 | 1.420 (0.643–3.139) | 0.386 |
 RUNX1 mutation | 1.165 (0.723–1.876) | 0.531 | 1.426 (0.753–2.702) | 0.276 |
 SF3B1 mutation | 1.251 (0.743–2.153) | 0.387 | 1.423 (0.613–3.305) | 0.412 |
 TP53 mutation | 8.517 (5.005–14.492) | < 0.001 | 8.885 (4.077–19.365) | < 0.001 |